TEMPUS EXPANDS AI-ENABLED CARE PATHWAY INTELLIGENCE PLATFORM INTO BREAST CANCER /// READ MORE TEMPUS EXPANDS AI-ENABLED CARE PATHWAY INTELLIGENCE PLATFORM INTO BREAST CANCER /// READ MORE
ORDER A TEST Log In Contact Us

NEWS

Press Releases

Media Coverage

Additional Partnerships

Filter By
For all media inquiries, please contact media@tempus.com
  • 02/18/2025

    Tempus to Participate in the Morgan Stanley Technology, Media and Telecom Conference

    Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, will participate in the Morgan Stanley Technology, Media & Telecom Conference on Monday, March 3-6, 2025, held in San Francisco, CA. Tempus Founder and CEO, Eric Lefkofsky, will participate in...

  • 02/13/2025

    Tempus Announces Collaboration with IFLI Aimed at Supporting Development of Targeted Therapies for Follicular Lymphoma

    Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a new collaboration with the Institute for Follicular Lymphoma Innovation (IFLI), a global, non-profit, private foundation dedicated to accelerating the development of innovative treatme...

  • 02/11/2025

    Tempus to Report Fourth Quarter and Full Year 2024 Financial Results on February 24

    Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the fourth quarter and full year 2024 on Monday, February 24, 2025. The company will hold the earnings conference call at 4:30 p.m. ET. The company’s quarterly earnings will...

  • 02/03/2025

    Tempus Completes Acquisition of Ambry Genetics

    Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced it has completed its acquisition of Ambry Genetics, a recognized leader in genetic testing that aims to improve health by understanding the relationship between genetics and...

  • 01/21/2025

    Tempus Announces National Launch of olivia, its AI-enabled Personal Health Concierge App for Patients

    Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the national launch of olivia. olivia is an AI-enabled personal health concierge app designed to empower patients by bringing their health-related data into one central location and leverag...

  • 01/15/2025

    Tempus Announces the National Launch of FDA-Approved xT CDx Test

    Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the national launch of the company’s FDA-approved, NGS-based in vitro diagnostic device, xT CDx. Beginning today, xT CDx is now available for all ordering clinicians...

  • 01/14/2025

    Tempus One Introduces New GenAI Capabilities to Query Millions of Unstructured Documents for Research and Clinical Care

    Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today introduced a suite of new, transformative capabilities available in Tempus One, the company’s generative AI assistant. Tempus One, which initially launched in 2023, provides both physicians and...

  • 01/13/2025

    Tempus Announces Its First-Ever, Whole-Genome Sequencing Assay, xH

    Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the company is developing its first whole-genome sequencing test, xH. This test marks Tempus’ first foray into adopting whole-genome sequencing (WGS) as a platform, supporting clinicians with detection of all c...

  • 01/13/2025

    Tempus Announces Preliminary Fourth Quarter and Full Year 2024 Results

    Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced select, preliminary, unaudited results for the fourth quarter and full year ended December 31, 2024. Full Year 2024 Select, Preliminary, Unaudited Financial Results Revenue of approximately $693 million, represen...

  • 01/08/2025

    Tempus Announces a Collaboration with Genialis to Develop RNA-based Biomarker Algorithms

    Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a collaboration with Genialis, the RNA-biomarker company. The multi-year agreement allows Genialis to leverage Tempus’ multimodal dataset to develop new RNA-based algorithms across cancer types. Clinical...

3 4 5